Drugs / Meningococcal Group B Vaccine
Meningococcal Group B Vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04722003 | Nov 2021 → Oct 2023 | gonorrhea | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04318548 | Aug 2020 → Nov 2023 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03632720 | Oct 2018 → Dec 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04094883 | Oct 2019 → Sep 2020 | gonorrhea | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06647407 Comparator | Nov 2024 → May 2027 expected | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal group B vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06647407 ↗ |
| Known as | 4CMenB | “multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R))” NCT04722003 ↗ |
| Known as | Bexsero (R) | “multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R))” NCT04722003 ↗ |
| Known as | GSK3536829A | “Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)” NCT04318548 ↗ |
| Known as | rMenB+OMV NZ | “Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)” NCT04318548 ↗ |
| Modality | Vaccine | “Meningococcal group B vaccine” NCT03632720 ↗ |
| Route | Intramuscular | “route of administration: deep intramuscular” NCT03632720 ↗ |